Introduction {#section1-1559325819876766}
============

Statins are hydroxymethylglutaryl-CoA reductase inhibitors, widely prescribed for various types of dyslipidemia to reduce cardiovascular risk. Most clinical guidelines recommend statin use for primary and secondary cardiovascular prevention or treatment.^[@bibr1-1559325819876766],[@bibr2-1559325819876766]^ Diabetes is one of the high-risk factors for cardiovascular disease, as is stated in clinical guidelines.^[@bibr1-1559325819876766],[@bibr2-1559325819876766]^ One study published in 1998 showed that diabetes can be considered as a myocardial infarction or a risk equivalent state.^[@bibr3-1559325819876766]^ A review article presented the links between diabetes and cardiovascular disease.^[@bibr4-1559325819876766]^ Consistent with the findings of these studies, statins have been prescribed for diabetic patients worldwide. However, there are numerous subtypes of statin exhibiting structural differences, and these differences cause various pharmacokinetics or efficacy. In general, statins are classified into hydrophilic or lipophilic groups on the basis of tissue selectivity. In our studies, there were rosuvastatin and pravastatin in the hydrophilic group and there were atorvastatin, simvastatin, fluvastatin, and lovastatin in the lipophilic group. No standard recommendations exist for selecting a hydrophilic or lipophilic statin in clinical practice. Our 12-year follow-up study was designed to enable evaluating the benefits of hydrophilic or hydrophobic statins for diabetic patients in Asia.

Methods {#section2-1559325819876766}
=======

Data Source {#section3-1559325819876766}
-----------

The universal National Health Insurance (NHI) program was implemented in Taiwan in March 1995 as a compulsory single-payer health-care system. By 2011, it had achieved a coverage rate of approximately 99.9% of the 23.22 million Taiwanese citizens.^[@bibr5-1559325819876766],[@bibr6-1559325819876766]^ The substantial computerized database that became the National Health Insurance Research Database (NHIRD) was derived from the NHI program and is maintained by the National Health Research Institutes. The identification numbers of all people in the NHIRD are encrypted to protect privacy. In this study, we used the data set from the Longitudinal Health Insurance Database 2000 (LHID2000). It contains the original claims data of 1 000 000 claims, randomly sampled from the 2000 Registry for Beneficiaries of the NHIRD, which has been demonstrated to be representative of the entire population. Patient diagnoses were coded according to the *International Classification of Diseases, Ninth Revision, Clinical Modification* (*ICD-9-CM*). Taiwan launched an NHI in 1995, operated by a single buyer, the government. Medical reimbursement specialists and peer review should scrutinize all insurance claims. The diagnoses of cardiovascular events were based on the *ICD-9* codes which were judged and determined by related specialists and physicians according to the standard clinical criteria. Therefore, the diagnoses and codes for cardiovascular events used in this study should be correct and reliable.

Ethics Statement {#section4-1559325819876766}
----------------

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the institutional review board (IRB) of China Medical University (CMUH-104-REC2-115-CR4). The IRB also specifically waived the consent requirement.

Sampled Participants {#section5-1559325819876766}
--------------------

[Figure 1](#fig1-1559325819876766){ref-type="fig"} shows the selection process of the participants in the study cohorts. The study patients were identified from the LHID2000 as newly diagnosed cases with type 2 diabetes mellitus (T2DM; *ICD-9-CM* 250.x0 and 250.x2) during the period from January 2000 to December 2011. The patients with T2DM were divided into 2 cohorts according to their statin use: the hydrophilic statin cohort included patients who had received hydrophilic statin therapy for at least 6 months (180 days) and the lipophilic statin cohort included patients who had received lipophilic statin therapy for at least 6 months (180 days). Among the 2 cohorts, patients with a history of coronary artery disease (CAD; *ICD-9-CM* codes 410-414), acute myocardial infarction (AMI; *ICD-9-CM* code 410), congestive heart failure (CHF; *ICD-9-CM* code 428), atrial fibrillation (AF; *ICD-9-CM* code 427.31), and stroke (*ICD-9-CM* codes 430-438) before the index date, patients under 20 years of age, and those with incomplete medical information were excluded.

![Selection process of the participants in the study cohorts.](10.1177_1559325819876766-fig1){#fig1-1559325819876766}

Outcome {#section6-1559325819876766}
-------

Cardiovascular events included CAD, AMI, CHF, AF, and stroke. All study patients were followed from the index date to the development of cardiovascular events, loss to follow-up, withdrawal from the insurance program, or December 31, 2011.

Baseline Variables {#section7-1559325819876766}
------------------

We obtained baseline variables investigated in this study, including sociodemographic status (including sex, age, monthly income, and urbanization level), comorbidities of hypertension (*ICD-9-CM* codes 401 to 405), chronic obstructive pulmonary disease (*ICD-9-CM* codes 491, 492, 496), chronic kidney disease (*ICD-9-CM* codes 580-589), and arrhythmia (*ICD-9-CM* code 426, 427), and medications including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, metformin, aspirin, and insulin.

Statistical Analysis {#section8-1559325819876766}
--------------------

We compared the distributions of sociodemographic status, comorbidities, and medications between the cohorts with hydrophilic statin and with lipophilic statin use by using a Pearson χ^2^ test for categorical variables and a Student *t* test for continuous variables. The overall sex-specific incidence densities of cardiovascular events were measured among the 2 cohorts. Univariable and multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for cardiovascular events in patients with T2DM with lipophilic statin use in relationship to the hydrophilic statin use. The multivariable models simultaneously adjusted for sociodemographic status, comorbidities, and medications. The cumulative incidence of cardiovascular events among the 2 cohorts was plotted using the Kaplan-Meier method and the difference was tested using a log-rank test. All data analyses were performed using SAS 9.3 software (SAS Institute, Cary, North Carolina) for Windows. The level of significance was set at .05, and the tests were 2-tailed.

Results {#section9-1559325819876766}
=======

This study involved 4259 patients who used hydrophilic statin and 8637 patients who used lipophilic statin ([Table 1](#table1-1559325819876766){ref-type="table"}). Among the 2 cohorts, most patients were aged 50 to 64 years (50.7% in the hydrophilic statin use cohort and 49.4% in the lipophilic statin use cohort) and were female (52.6% in the hydrophilic statin use cohort and 52.1% in the lipophilic statin use cohort). Compared with patients in the lipophilic statin cohort, the patients in the hydrophilic statin cohort exhibited a higher tendency to have high monthly incomes (34.3% vs 32.0% for monthly income ≥20 000) and live in urbanized areas (64.8% vs 61.0% in urbanization levels 1 and 2). Comorbidities were more prevalent in the hydrophilic statin cohort than in the lipophilic statin cohort, particularly hypertension (69.3% vs 65.4%). The prevalence of medications was higher in the hydrophilic statin cohort than in the lipophilic statin cohort.

###### 

Comparison of Demographics and Comorbidity Between Hydrophilic and Lipophilic Statin Use.^a^

![](10.1177_1559325819876766-table1)

                          Type 2 Diabetes   *P* Value                 
  ----------------------- ----------------- ----------- ------ ------ --------
  Age, years                                                          .001
   ≤49                    919               21.6        2103   24.4   
   50-64                  2158              50.7        4264   49.4   
   \>65                   1182              27.8        2270   26.3   
  Mean (SD)^b^                                                        
  Gender                                                              .59
   Women                  2240              52.6        4499   52.1   
   Men                    2019              47.4        4138   47.9   
  Monthly income (NTD)                                                .027
   \<15 000               766               18.0        1604   18.6   
   15 000-19 999          2031              47.7        4272   49.5   
   ≥20 000                1462              34.3        2761   32.0   
  Urbanization level^c^                                               \<.001
   1 (highest)            1422              33.4        2667   30.9   
   2                      1336              31.4        2600   30.1   
   3                      770               18.1        1479   17.1   
   4                      731               17.2        1891   21.9   
  Comorbidity                                                         
   Hypertension           2951              69.3        5651   65.4   \<.001
   COPD                   480               11.3        956    11.1   .73
   CKD                    578               13.6        1106   12.8   .22
   Arrhythmia             242               5.68        470    5.44   .57
  Medications                                                         
   ACEI                   2157              50.7        4106   47.5   \<.001
   AIIRBs                 1939              45.5        2880   33.3   \<.001
   β-Blockers             2240              52.6        4311   49.9   .004
   Metformin              3518              82.6        6894   79.8   \<.001
   Aspirin                1778              41.8        3197   37.0   \<.001
   Insulin                2591              60.8        5074   58.8   \<.001

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; AIIRB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; NTD, new Taiwan dollar; SD, standard deviation.

^a^ Chi-square test comparing subjects with hydrophilic statin use and lipophilic statin use.

^b^ *T* test.

^c^ The urbanization level was categorized by the population density of the residential area into 4 levels, with level 1 as the most urbanized and level 4 as the least urbanized.

With 12-year follow-up, Kaplan-Meier analysis was adopted to calculate the cumulative incidence of CAD, AMI, CHF, and stroke, as shown in [Figure 1](#fig1-1559325819876766){ref-type="fig"}. The cumulative incidence of CAD and stroke was higher in patients of the lipophilic statin cohort than in those of the hydrophilic statin cohort ([Figure 2A](#fig2-1559325819876766){ref-type="fig"}, log-rank test: *P* \< .001, [Figure 2D](#fig2-1559325819876766){ref-type="fig"}, log-rank test: *P* \< .001).

![Cumulative incidences of coronary artery disease (A), acute myocardial infarction (B), congestive heart failure (C), and stroke (D) in patients with hydrophilic statin use, and with lipophilic statin use, compared to patients without statin use.](10.1177_1559325819876766-fig2){#fig2-1559325819876766}

The overall incidences of CAD were 21.6 and 31.6 per 1000 person-years in the hydrophilic statin and lipophilic statin cohorts, respectively ([Table 2](#table2-1559325819876766){ref-type="table"}). After adjusting for age, sex, comorbidities, and medication, the risk of CAD and stroke in the lipophilic statin use cohort was 54% and 46% higher (significantly) than in the hydrophilic statin use cohort. Among men patients, the risk of CAD in the lipophilic statin use cohort was 49% higher (significantly) than in the hydrophilic statin use cohort. Among women patients, the risk of CAD, CHF, and stroke in the lipophilic statin use cohort was 58%, 43%, and 66% higher (significantly) than in the hydrophilic statin use cohort.

###### 

Comparisons of Incidence Densities and Hazard Ratio of Cardiovascular Outcomes in Study Cohorts.

![](10.1177_1559325819876766-table2)

            Hydrophilic Statin Use   Crude HR^b^ (95% CI)   Adjusted HR^c^ (95% CI)   Lipophilic Statin Use   Crude HR^b^ (95% CI)   Adjusted HR^c^ (95% CI)                         
  --------- ------------------------ ---------------------- ------------------------- ----------------------- ---------------------- ------------------------- --------------------- ---------------------
  All                                                                                                                                                                                
   CAD      262                      21.6                   1 (Reference)             1 (Reference)           1000                   31.6                      1.48 (1.29-1.69)^d^   1.54 (1.35-1.77)^d^
   AMI      41                       3.19                   1 (Reference)             1 (Reference)           140                    3.98                      1.12 (0.79-1.60)      1.12 (0.79-1.59)
   CHF      113                      8.93                   1 (Reference)             1 (Reference)           373                    10.8                      1.18 (0.96-1.46)      1.23 (0.99-1.52)
   AF       28                       2.17                   1 (Reference)             1 (Reference)           92                     2.61                      1.11 (0.72-1.69)      1.15 (0.75-1.76)
   Stroke   147                      11.7                   1 (Reference)             1 (Reference)           560                    16.5                      1.39 (1.16-1.67)^d^   1.46 (1.22-1.76)^d^
  Men                                                                                                                                                                                
   CAD      121                      22.1                   1 (Reference)             1 (Reference)           461                    31.2                      1.44 (1.17-1.76)^d^   1.49 (1.22-1.83)^d^
   AMI      22                       3.82                   1 (Reference)             1 (Reference)           73                     4.48                      1.07 (0.66-1.74)      1.06 (0.65-1.72)
   CHF      53                       9.31                   1 (Reference)             1 (Reference)           145                    9.03                      0.95 (0.69-1.30)      0.99 (0.72-1.36)
   AF       14                       2.42                   1 (Reference)             1 (Reference)           40                     2.44                      0.88 (0.47-1.62)      0.92 (0.50-1.72)
   Stroke   73                       13.0                   1 (Reference)             1 (Reference)           253                    16.1                      1.21 (0.93-1.58)      1.26 (0.97-1.64)
  Women                                                                                                                                                                              
   CAD      141                      21.2                   1 (Reference)             1 (Reference)           539                    32.0                      1.52 (1.26-1.83)^d^   1.58 (1.31-1.90)^d^
   AMI      19                       2.68                   1 (Reference)             1 (Reference)           67                     3.55                      1.17 (0.70-1.95)      1.18 (0.70-1.98)
   CHF      60                       8.61                   1 (Reference)             1 (Reference)           228                    12.4                      1.40 (1.06-1.87)^e^   1.43 (1.07-1.91)^e^
   AF       14                       1.97                   1 (Reference)             1 (Reference)           52                     2.75                      1.33 (0.74-2.42)      1.36 (0.74-2.48)
   Stroke   74                       10.7                   1 (Reference)             1 (Reference)           307                    17.0                      1.57 (1.22-2.03)^d^   1.66 (1.29-2.15)^d^

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; AIIRB, angiotensin II receptor blocker; AMI, acute myocardial infarction; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; HR, hazard ratio.

^a^ Rate, incidence rate, per 1000 person-years.

^b^ Crude HR, relative hazard ratio.

^c^ Adjusted HR: Multivariable analysis including age, sex, monthly income, urbanization level, comorbidity of hypertension, COPD, CKD, and arrhythmia, and medication of ACEI, AIIRB, β-blockers, metformin, aspirin, and insulin.

^d^ *P* \< .001.

^e^ *P* \< .05.

The risk of CAD was higher in men with lipophilic statin use (HR = 1.74, 95% CI = 1.43-2.11) and women with lipophilic statin use (HR = 1.58, 95% CI = 1.31-1.91) than in women with hydrophilic statin use ([Table 3](#table3-1559325819876766){ref-type="table"}). Compared with women who used hydrophilic statin, men who used lipophilic statin exhibited a higher risk of AMI (HR = 1.74, 95% CI = 1.04-2.91). Compared with women who used hydrophilic statin, men who used lipophilic statin were 1.87-fold more likely to develop stroke (95% CI = 1.44-2.43), followed by women who used lipophilic statin (HR = 1.66, 95% CI = 1.29-2.14) and men who used lipophilic statin (HR = 1.48, 95% CI = 1.07-2.05).

###### 

Development of CAD, AMI, and Stroke in Patients With Statin Use Associated With Gender in Cox Regression Analysis.

![](10.1177_1559325819876766-table3)

  Hydrophilic Statin Use   Lipophilic Statin Use   Gender   N      Case   Rate^a^   Crude HR^b^ (95% CI)   Adjusted HR^c^ (95% CI)
  ------------------------ ----------------------- -------- ------ ------ --------- ---------------------- -------------------------
  CAD                                                                                                      
   Yes                     No                      Women    2240   141    21.2      1 (Reference)          1 (Reference)
   Yes                     No                      Men      2019   121    22.1      1.04 (0.82-1.32)       1.16 (0.91-1.48)
   No                      Yes                     Women    4499   539    32.0      1.52 (1.27-1.83)^d^    1.58 (1.31-1.91)^d^
   No                      Yes                     Men      4138   461    31.2      1.48 (1.23-1.79)^d^    1.74 (1.43-2.11)^d^
  AMI                                                                                                      
   Yes                     No                      Women    2240   19     2.68      1 (Reference)          1 (Reference)
   Yes                     No                      Men      2019   22     3.82      1.48 (0.80-2.73)       1.65 (0.89-3.07)
   No                      Yes                     Women    4499   67     3.55      1.20 (0.72-2.00)       1.19 (0.71-1.99)
   No                      Yes                     Men      4138   73     4.48      1.55 (0.93-2.57)       1.74 (1.04-2.91)^e^
  Stroke                                                                                                   
   Yes                     No                      Women    2240   74     10.7      1 (Reference)          1 (Reference)
   Yes                     No                      Men      2019   73     13.0      1.22 (0.89-1.69)       1.48 (1.07-2.05)^e^
   No                      Yes                     Women    4499   307    17.0      1.57 (1.21-2.02)^d^    1.66 (1.29-2.14)^d^
   No                      Yes                     Men      4138   253    16.1      1.49 (1.15-1.93)^e^    1.87 (1.44-2.43)^d^

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; AIIRB, angiotensin II receptor blocker; AMI, acute myocardial infarction; CAD, coronary artery disease; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; HR, hazard ratio.

^a^ Rate, incidence rate, per 1,000 person-years.

^b^ Crude HR, relative hazard ratio.

^c^ Adjusted HR: multivariable analysis including age, sex, monthly income, urbanization level, comorbidity of hypertension, COPD, CKD, and arrhythmia, and medication of ACEI, AIIRB, β-blockers, metformin, aspirin, and insulin.

^d^ *p* \< 0.001.

^e^ *p* \< 0.05 .

Discussion {#section10-1559325819876766}
==========

In our study, we separated 2 statin group cohorts including hydrophilic statin cohort such as rosuvastatin and pravastatin users and lipophilic statin cohort such as atorvastatin, simvastatin, fluvastatin, and lovastatin users. Patients in the hydrophilic statin cohort were mostly older than 50 years old, female, had a high monthly income, lived in urbanized areas, and exhibited comorbidities with hypertension. Multiple medications such as antihypertension, oral antidiabetic agents, and insulin were prescribed in our hydrophilic statin cohort.

Sex and Hydrophilic or Lipophilic Statin {#section11-1559325819876766}
----------------------------------------

The Cholesterol Treatment Trialists' Collaboration suggested that statin therapy is of similar effectiveness in the prevention of major vascular events among men and women.^[@bibr7-1559325819876766]^ One study showed that high low-density lipoprotein (LDL) cholesterol levels were significantly associated with cardiovascular events among men and women, but there was a stronger association for stroke in women and for coronary heart disease death in men.^[@bibr8-1559325819876766]^ In our study, most cardiovascular events such as CAD and stroke in patients used lipophilic statin. Among men patients, the risk of CAD in the lipophilic statin use cohort was significantly higher than other men in the hydrophilic statin use cohort.

Among women patients, the risk of CAD, CHF, and stroke in the lipophilic statin use cohort was significantly higher than other women in the hydrophilic statin use cohort. Different races or hormone effects in women are possible explanations. We suggest that hydrophilic statin may be the optimal choice for diabetic Asian for reducing the occurrence of cardiovascular events.

Hydrophilic or Lipophilic Statins for Cardiovascular Events {#section12-1559325819876766}
-----------------------------------------------------------

In our study, no benefit was observed for AF in diabetic patients of both statin cohorts. Atrial fibrillation is another independent risk factor for cardiovascular death.^[@bibr9-1559325819876766]^ However, previous studies have shown that lipophilic statin with atorvastatin was superior to hydrophilic statin with pravastatin on AF issue.^[@bibr10-1559325819876766]^ Statin therapy for CHF was considered controversial in other studies.^[@bibr11-1559325819876766],[@bibr12-1559325819876766]^ In our study, no benefit was observed in both statin cohorts and both sexes. A 2-year comparison of hydrophilic and lipophilic statin studies showed no significant difference in AMI.^[@bibr13-1559325819876766]^ A 1-year cardiovascular outcomes study suggested that lipophilic statin was superior for AMI.^[@bibr14-1559325819876766]^ However, another study showed that hydrophilic statin was superior to lipophilic statin in the prevention of new-Q wave formation in patients with AMI.^[@bibr15-1559325819876766]^ Our long-term study showed that hydrophilic statin was superior to lipophilic statin in diabetic patients with CAD, and stroke.

Hydrophilic Versus Lipophilic Statins {#section13-1559325819876766}
-------------------------------------

In our study, the incidence of CAD and stroke was strongly associated in the lipophilic statin cohort; for the male group, the incidences of CAD were higher in the lipophilic statin cohort, but for the female group, the incidences of CAD, CHF, and stroke were higher in the lipophilic statin cohort. In addition to a lipid-lowering effect, numerous pleiotropic effects are associated with statin use, such as a reduction in inflammation and vascular thrombus and an improvement in endothelial functions.^[@bibr16-1559325819876766][@bibr17-1559325819876766]--[@bibr18-1559325819876766]^ Hydrophilic statin exhibits lower tissue absorption and lower dependence on the cytochrome P450 enzyme compared with lipophilic statin; therefore, fewer side effects occur in the use of hydrophilic statin.^[@bibr19-1559325819876766]^ According to one study, compared with lipophilic statin, hydrophilic statin was superior in attenuating inflammation.^[@bibr20-1559325819876766]^ These are the possible mechanisms explaining our cardiovascular outcomes. The retrospective cohort study is usually lower evidence than the randomized controlled trials because a retrospective cohort study is subject to have many unknown or uncontrolled confounding factors. Further study is needed to evaluate the association between hydrophilic and lipophilic statin.

Limitations {#section14-1559325819876766}
-----------

The retrospective cohort study is usually lower evidence than the randomized controlled trials because a retrospective cohort study is subject to have many unknown or uncontrolled confounding factors. Another limitation of our study was that cardiovascular diseases are asymptomatic or underdiagnosed. Based on the NHIRD, we could not collect patients' other risk factors for cardiovascular events such as lifestyle, alcohol consumption, salt intake, nutritional status, weight and height, and smoking habit. Because of the lack of individual laboratory data (such as cholesterol, LDL or high-density lipoprotein, fasting blood sugar, or hemoglobin A~1C~ \[HbA~1C~\]) and for the study subjects in the NHIRD, we did not do analyses of the cholesterol reduction after different statin treatments and measures of diabetes (eg, fasting blood glucose or HbA~1C~) between these subgroups. Image data such as radiologic results or heart echo finding were also not offered by NHIRD. Of course, if the patient could absolutely follow these doctors' order to regularly receive the statin therapy (patient compliance) should be considered as one of the other study limitations for this study.

Conclusion {#section15-1559325819876766}
==========

Hydrophilic and lipophilic statin therapy for dyslipidemia is still controversial in clinical practice. According to our long-term cohort study, hydrophilic statin use may be a better choice than lipophilic statin to reduce cardiovascular events in Asian diabetic patients.
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